Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis

• Objectives

Primary Objective: To compare the effect on the evolution of organ failures of two initiation strategies of etoposide in severe HLH in intensive care:

• An early strategy where etoposide is initiated within 12 hours after inclusion.
• A delayed strategy where this treatment is initiated only in case of unfavorable evolution (or lack of improvement) after 48 hours.

The occurrence of an event defined as the onset or worsening of organ failures, evaluated using the modified Sequential Organ Failure Assessment (SOFA) score (excluding the hematologic component, from 0 to 20 points), calculated every 12 hours from Day 1 to Day 5 (Day 0 = inclusion), and then every 24 hours from Day 6 to Day 14. An event will be defined as an increase of at least 1 point for at least two organ systems compared to Day 0. In the delayed arm, the use of rescue etoposide treatment or in case of secondary aggravation during follow-up will also be considered an event.

Secondary objectives:

• Evaluate the effect of these 2 strategies on:

• Survival
• Duration of mechanical ventilation
• Duration of catecholamine therapy
• Need for renal replacement therapy
• Length of stay in the intensive care unit
• Length of hospital stay
• Proportion of patients receiving etoposide treatment
• Cumulative dose of etoposide
• Time to initiation of etoposide treatment
• Number of patients receiving another immunosuppressive treatment
• Normalization of HLH-related biological abnormalities
• Evolution of the HScore (probability score for HLH)
• Potential side effects attributable to etoposide, such as healthcare-associated infections, incidence of neutropenia, and bleeding events.
• Evolution of the SOFA score and modified SOFA score
• Identify risk factors for mortality in severe HLH in intensive care.
• Identify and describe comorbidities associated with severe HLH in intensive care, and their prognostic impact.
• Investigational treatment

Etoposide is used at a dose of 100 mg/m², administered via slow intravenous infusion over 30 to 60 minutes on Day 0 or Day 2 depending on the arm (early strategy or delayed strategy).

Patients in the "early strategy" arm will receive etoposide treatment within 12 hours of inclusion.

In the "delayed strategy" arm, patients will be reassessed 48 hours after inclusion. If there is persistence or deterioration of organ failures (similar or higher modified SOFA score), patients will receive etoposide treatment within 12 hours of this reassessment in the absence of formal contraindications. In cases of rapidly deteriorating clinical status with short-term life-threatening prognosis (defined as an increase of 6 or more points in modified SOFA score), patients may receive rescue treatment (before 48 hours) with etoposide at the discretion of the medical team managing the patient; in such cases, the Day-2 infusion will not be administered. This practice will be exceptional and documented, following consultation with the hotline if possible.

In the unlikely event of subsequent clinical deterioration from Day 2 to Day 14, etoposide infusion may be considered for patients who did not receive etoposide previously in the "delayed strategy" group. This situation will also be documented.

Patients in both arms will routinely receive systemic corticosteroid therapy with dexamethasone 10 mg/m² in a daily injection for the duration of the study, unless contraindicated (adjuvant investigational drug).

• Standard treatment

In case of persistence of HLH signs, a first (for patients in the "delayed strategy" arm) or subsequent (for patients in both arms) injections of etoposide may be performed during follow-up at the discretion of the patient's care team.

Other treatments will be:

• Additional injections of etoposide if signs of hemophagocytic lymphohistiocytosis persist, at least 7 days after the previous administration, if applicable.
• Treatment of conditions associated with HLH according to current recommendations and after expert consultation where appropriate.
• In case of clinical deterioration and based on associated conditions, after consultation with experts (hematologist, internist, or immunologist depending on the center), administration of other immunosuppressive treatments may be considered, according to current recommendations and at the discretion of the patient's medical team.
• Practical procedure Recruitment will take place in the investigational ICUs. Inclusion and exclusion criteria will be verified for all patients admitted to the intensive care unit with suspected secondary HLH. Patients meeting all inclusion criteria and having no exclusion criteria will be invited to participate in the study. Patient information and consent will be handled by the intensivist.

Inclusion and randomization will be conducted through a computer server accessible to all study investigators. This will be a 1:1 randomization into two groups, with stratification based on the SOFA score (<9 or ≥9), prior administration of corticosteroid therapy, and the centers.

The 2 groups will be:

• The "early strategy" group
• The "delayed strategy" group

Data will be collected as part of routine care for HLH management (clinical and biological characteristics, dates of HLH onset and diagnosis, underlying immunosuppression, HLH-associated pathologies, HScore and Henter criteria, immunomodulatory treatments [date, duration], daily assessment of organ support, occurrence of infectious or hemorrhagic events) by the investigator, and recorded in an e-CRF. Data collection will continue up to 14 days post-randomization. SOFA score and modified SOFA score (excluding hematological component) will be calculated and recorded by the investigator every 12 hours from Day 1 to Day 5, then daily from Day 6 to Day 14. Adverse events will be reported from inclusion to Day 14. Vital status will be collected on Day 14 and Day 60, with a maximum follow-up duration of 60 days. A systematic minimal assessment for HLH-associated pathologies will be proposed to each team.

The protocol also includes the establishment of a biobank (serotheca and DNAtheca) at the PRB of Avicenne Hospital.

Inclusion criteria

• Adult patient
• Confirmed diagnosis of HLH:

• Hscore ≥ 169
• Diagnosis of HLH established by the multidisciplinary team caring for the patient(A 24/7 hotline will be available in case of diagnostic uncertainty: this will be the direct line to the on-call intensivist at Avicenne Hospital, who can contact the coordinating investigator as needed)
• First episode of HLH
• Admission to intensive care unit
• Presence of one or more organ failures:

• Circulatory: mBP < 65 mmHg with lactate > 2 mmol/L, or treatment with catecholamines
• Respiratory: oxygen therapy > 6 L/min or need for non-invasive ventilation, high-flow nasal cannula oxygen therapy, or invasive mechanical ventilation
• Renal: stage 2 or higher according to KDIGO criteria, defined by a creatinine increase ≥ 2 times baseline, or urine output < 0.5 mL/kg/h for ≥ 12 hours, or initiation of renal replacement therapy
• Neurological: GCS ≤ 13

Exclusion criteria

• Moribund patient with refractory distributive shock: multi-organ failure requiring noradrenaline > 2.5 µg/kg/min and imminent risk of death.
• Inability to administer etoposide within 12 hours.
• Patient treated with etoposide prior to admission to the intensive care unit.
• Hypersensitivity to etoposide or any of its excipients.
• Hypersensitivity or contraindication to dexamethasone or any of its excipients, as described in the package insert for the dexamethasone specialty used in the trial and in the protocol.
• Patient with a history of CAR-T cell therapy.
• Patient developing HLH within 15 days following chemotherapy for cancer or hematologic malignancy.
• Patient not covered by social security.
• Patient under legal guardianship, tutelage, or curatorship.
• Minor patient.
• Pregnant women (positive βhCG), women for whom pregnancy has not been excluded (βhCG not performed in women of childbearing age), or lactating women.
• Recent vaccination with a live attenuated vaccine.
• Participation in another interventional research study.